Immunotherapy leading the new wave of cancer treatment
Pioneering immunotherapy drugs are offering new hope to patients with hard-to-treat advanced cancers.
Early clinical trials of one experimental agent, nivolumab, have proven so promising that an application to fast-track its use for lung cancer is being made in the US, while another drug, ipilimumab, is already marketed for melanoma.
New data to be presented later this month indicates that nivolumab can significantly improve the survival of patients with advanced melanoma, lung and kidney cancers.
Both drugs are produced by the pharmaceutical company Bristol Myers Squibb (BMS), which has invested